https://scholars.lib.ntu.edu.tw/handle/123456789/454622
標題: | CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine | 作者: | Lin K.-M. Tsou H.-H. Tsai I.-J. Hsiao M.-C. Hsiao C.-F. Liu C.-Y. Shen W.W. Tang H.-S. Fang C.-K. CHI-SHIN WU SHAO-CHUN LU Kuo H.-W. Liu S.C. Chan H.-W. Hsu Y.-T. Tian J.-N. Liu Y.-L. |
公開日期: | 2010 | 卷: | 11 | 期: | 11 | 起(迄)頁: | 1535-1543 | 來源出版物: | Pharmacogenomics | 摘要: | Aim: Paroxetine is a drug of choice in the treatment of major depressive disorder (MDD). Its metabolism has recently been reported to be mediated through the CYP enzymes 1A2 and 2D6. In our current study, we tested whether genetic polymorphisms in CYP1A2 are associated with the treatment efficacy and side effects of paroxetine. Materials & methods: A total of 241 MDD patients who had taken paroxetine continually for 8 weeks were recruited, and their steady state paroxetine concentrations were measured at weeks 2, 4 and 8. The genotypes of these patients were then assessed for the presence of nine SNPs, which were selected from either the HapMap Chinese ethnic group, the literature report or through their functional role in the CYP1A2 gene. Results: The allele types for SNPs rs4646425 (permutation p = 0.03), rs2472304 (permutation p = 0.01) and rs2470890 (permutation p = 0.004) demonstrated significant associations with paroxetine treatment remission at week 8. Response rates in the Hamilton Rating Scale for Depression (HAM-D) and for The Hamilton Rating Scale for Anxiety (HAM-A) were significantly associated with the SNPs rs4646425 (p = 0.0126 and 0.0088 for HAM-D and HAM-A, respectively) and rs4646427 (p = 0.0067 and 0.0196 for HAM-D and HAM-A, respectively). The inducible SNP rs762551 had a significant association with paroxetine dose at week 4 (permutation p = 0.012). We did not find an association between these SNPs and the side effects or serum concentrations of paroxetine. Conclusion: Genetic variants in the CYP1A2 region may be indicators of treatment response in MDD patients to paroxetine. ? 2010 Future Medicine Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-78649706451&doi=10.2217%2fpgs.10.128&partnerID=40&md5=2b42b78264c73fcc2b110fd3b30e3219 https://scholars.lib.ntu.edu.tw/handle/123456789/454622 |
ISSN: | 1462-2416 | DOI: | 10.2217/pgs.10.128 | SDG/關鍵字: | cytochrome P450 1A2; imipramine; lorazepam; paroxetine; zolpidem; adult; anxiety disorder; article; blood sampling; Chinese; controlled study; diagnostic and statistical manual of mental disorders; drug blood level; drug efficacy; drug response; ethnicity; evening dosage; female; gene frequency; gene linkage disequilibrium; gene locus; genetic polymorphism; genotype; Hamilton Anxiety Scale; Hamilton scale; haplotype; haplotype map; human; major clinical study; major depression; male; onset age; protein function; single nucleotide polymorphism; steady state; Adult; Antidepressive Agents, Second-Generation; Cohort Studies; Cytochrome P-450 CYP1A2; Depressive Disorder, Major; Female; Humans; Male; Paroxetine; Polymorphism, Single Nucleotide; Treatment Outcome |
顯示於: | 生物化學暨分子生物學科研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。